Getagraph.com logo
S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Sanntidsoppdatering for Karyopharm Therapeutics [KPTI]

Børs: NASDAQ Sektor: Healthcare Industri: Biotechnology
Upcoming Earnings Alert

5 days till quarter result
(bmo 2024-05-02)

Expected move: +/- 14.44%

BUY
25.00%
return -15.90%
SELL
40.00%
return -2.40%
Sist oppdatert26 apr 2024 @ 22:00
25% discount on Stockinvest.us - Use code: Podcast

0.00% $ 1.060

KJøP 104980 min ago

@ $1.418

Utstedt: 14 feb 2024 @ 21:43

Avkastning: -25.25%

Forrige signal: feb 13 - 18:41

Forrige signal: Selg

Avkastning: 12.54 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):
Profile picture for Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases...

Stats
Dagens volum 652 441
Gjennomsnittsvolum 1.79M
Markedsverdi 123.45M
EPS $0 ( 2024-02-29 )
Neste inntjeningsdato ( $-0.330 ) 2024-05-02
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.850
ATR14 $0.00200 (0.19%)
Insider Trading
Date Person Action Amount type
2024-04-22 Rangwala Reshma Sell 6 789 Common Stock
2024-04-04 Paulson Richard A. Sell 3 563 Common Stock
2024-03-05 Paulson Richard A. Sell 3 573 Common Stock
2024-02-29 Rangwala Reshma Sell 15 667 Common
2024-03-01 Rangwala Reshma Sell 5 969 Common
INSIDER POWER
69.84
Last 99 transactions
Buy: 2 857 011 | Sell: 554 783

Volum Korrelasjon

Lang: -0.29 (neutral)
Kort: -0.93 (very strong negative)
Signal:(25.667) Possible Trading Opportunity Present (swing)

Karyopharm Therapeutics Korrelasjon

10 Mest positive korrelasjoner
RMRM0.914
GAINL0.87
10 Mest negative korrelasjoner
BRAG-0.833
EM-0.806
AVTE-0.804
ARCE-0.803

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Karyopharm Therapeutics Korrelasjon - Valuta/Råvare

The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.50
( neutral )

Karyopharm Therapeutics Økonomi

Annual 2023
Omsetning: $146.03M
Bruttogevinst: $140.56M (96.25 %)
EPS: $-1.250
FY 2023
Omsetning: $146.03M
Bruttogevinst: $140.56M (96.25 %)
EPS: $-1.250
FY 2022
Omsetning: $157.07M
Bruttogevinst: $151.86M (96.68 %)
EPS: $-2.02
FY 2021
Omsetning: $209.82M
Bruttogevinst: $206.42M (98.38 %)
EPS: $-1.650

Financial Reports:

No articles found.

Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.